We are live on ! Find out more
SFM

Sphera Funds Management Portfolio holdings

AUM $630M
1-Year Est. Return 108.65%
This Fund
S&P 500
This Quarter Est. Return
+34.57%
1 Year Est. Return
+108.65%
3 Year Est. Return
+217.64%
5 Year Est. Return
+342.91%
10 Year Est. Return
+2,254.45%
AUM
$712M
AUM Growth
+$90.4M
Cap. Flow
+$220K
Cap. Flow %
0.03%
Top 10 Hldgs %
33.84%
Holding
126
New
27
Increased
25
Reduced
33
Closed
22

Top Buys

Rank Stock Value
1
CATX icon
Perspective Therapeutics
CATX
+$10.6M
2
BBIO icon
BridgeBio Pharma
BBIO
+$10.3M
3
HELP
Cybin Inc
HELP
+$9.73M
4
S icon
SentinelOne
S
+$8.81M
5
JSPR icon
Jasper Therapeutics
JSPR
+$7.71M

Top Sells

Rank Stock Value
1
NVMI
Nova
NVMI
+$15.3M
2
ATXS
Astria Therapeutics
ATXS
+$12.9M
3
TSEM icon
Tower Semiconductor
TSEM
+$10.9M
4
INBX
Inhibrx, Inc. Common Stock
INBX
+$8.61M
5
FUSN
Fusion Pharmaceuticals Inc. Common Shares
FUSN
+$7.61M

Sector Composition

Rank Sector Weight
1 Healthcare 65.19%
2 Technology 15.63%
3 Communication Services 2.68%
4 Consumer Discretionary 2.45%
5 Utilities 0.4%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ANRO icon
101
Alto Neuroscience
ANRO
$1.05B
$468K 0.07%
+30,500
New +$477K
IMTXW
102
DELISTED
Immatics N.V. Warrants
IMTXW
$270K 0.04%
100,000
– –
ARBE icon
103
Arbe Robotics
ARBE
$80.3M
$90.2K 0.01%
43,165
– –
ANNX icon
104
PUT
Annexon
ANNX
$834M
$81.7K 0.01%
+11,400
New +$59.2K
ALNY icon
105
Alnylam Pharmaceuticals
ALNY
$27.5B
– –
-36,230
Closed -$6.04M
APGE icon
106
Apogee Therapeutics
APGE
$10.1B
– –
-30,000
Closed -$838K
ARWR icon
107
Arrowhead Research
ARWR
$11.9B
– –
-144,899
Closed -$4.43M
CLDX icon
108
CALL
Celldex Therapeutics
CLDX
$2.99B
– –
-115,700
Closed -$4.59M
COGT icon
109
Cogent Biosciences
COGT
$6.65B
– –
-259,201
Closed -$1.52M
CYTK icon
110
CALL
Cytokinetics
CYTK
$10.5B
– –
-35,800
Closed -$2.99M
ENPH icon
111
CALL
Enphase Energy
ENPH
$4.96B
– –
-32,100
Closed -$4.24M
GILD icon
112
Gilead Sciences
GILD
$162B
– –
-20,000
Closed -$1.62M
GLUE icon
113
Monte Rosa Therapeutics
GLUE
$1.4B
– –
-48,511
Closed -$274K
MDGL icon
114
Madrigal Pharmaceuticals
MDGL
$10.8B
– –
-27,767
Closed -$6.42M
MDWD icon
115
MediWound
MDWD
$181M
– –
-48,980
Closed -$498K
ORIC icon
116
Oric Pharmaceuticals
ORIC
$1.15B
– –
-126,800
Closed -$1.17M
PANW icon
117
Palo Alto Networks
PANW
$270B
– –
-33,170
Closed -$4.89M
PRTA icon
118
CALL
Prothena Corp
PRTA
$425M
– –
-68,200
Closed -$2.48M
PTCT icon
119
PTC Therapeutics
PTCT
$5.68B
– –
-136,525
Closed -$3.76M
REPL icon
120
Replimune Group
REPL
$941M
– –
-16,096
Closed -$136K
RIGL icon
121
Rigel Pharmaceuticals
RIGL
$681M
– –
-122,813
Closed -$1.78M
SRPT icon
122
CALL
Sarepta Therapeutics
SRPT
$1.57B
– –
-26,400
Closed -$2.55M
MORF
123
DELISTED
Morphic Holding, Inc. Common Stock
MORF
– –
-14,952
Closed -$432K
GRCL
124
DELISTED
Gracell Biotechnologies Inc. American Depositary Shares
GRCL
– –
-502,936
Closed -$5.05M
FRLN
125
DELISTED
Freeline Therapeutics Holdings plc American Depositary Shares
FRLN
– –
-16,445
Closed -$105K
2 3 4
5
6

Similar funds

VIM
Vancity Investment Management Vancouver, British Columbia, Canada $629M AUM 2.49% 1-Year Est. Return
KCMH
Keywise Capital Management (HK) Hong Kong $630M AUM 81.01% 1-Year Est. Return
FCFC
First Commonwealth Financial Corp Indiana, Pennsylvania $629M AUM 20.47% 1-Year Est. Return
BI
BlueSpruce Investments Chicago, Illinois $631M AUM 11.83% 1-Year Est. Return
PWW
Pettyjohn Wood & White Lynchburg, Virginia $628M AUM 20.96% 1-Year Est. Return
TTSTC
Texas Treasury Safekeeping Trust Company Austin, Texas $628M AUM 15.58% 1-Year Est. Return
SWP
Summit Wealth Partners Orlando, Florida $632M AUM 9.71% 1-Year Est. Return
EIM
Essex Investment Management Boston, Massachusetts $632M AUM 95.36% 1-Year Est. Return

Sphera Funds Management's Q1 2024 Portfolio in Review

As of Q1 2024, Sphera Funds Management held 126 positions worth $712M, up 15% from $621M the previous quarter. Its ten largest holdings account for 34% of the portfolio.

Sphera Funds Management's Q1 2024 filing shows 27 new, 25 increased, 33 reduced and 22 closed positions. Its largest new stake was Cybin Inc: 673,195 shares worth $10.6M. The largest sale was Nova, an estimated $15.3M.

By sector, the portfolio is most concentrated in Healthcare at 65% of assets, up from 63% a quarter earlier, followed by Technology and Communication Services.

  • Sphera Funds Management's largest Q1 2024 buy was Cybin Inc: 673,195 shares worth $10.6M.
  • Sphera Funds Management added most to Perspective Therapeutics in Q1 2024, an estimated $10.6M increase.
  • Sphera Funds Management's biggest Q1 2024 reduction was Nova, cutting an estimated $15.3M.
  • Sphera Funds Management fully exited Inhibrx, Inc. Common Stock in Q1 2024, selling an estimated $8.61M.
  • Sphera Funds Management's ten largest holdings make up 34% of its $712M portfolio in Q1 2024.
  • Sphera Funds Management opened 27 new positions and closed 22 in Q1 2024.
  • Sphera Funds Management's portfolio value rose 15% quarter-over-quarter to $712M.

Based on Sphera Funds Management's 13F filing for Q1 2024, filed 15 May 2024.